Private GLP-1 prescriptions 32% lower in England's most deprived areas after obesity adjustment

The 2026 postcode-level review documented a clear inverse gradient between private semaglutide and tirzepatide uptake and local deprivation indices. After adjusting for higher obesity prevalence in lower-income quintiles, the per-person rate remained markedly lower where need is greatest. The provider data cannot establish causation but align with known barriers of out-of-pocket cost, limited specialist referral pathways, and lower private-insurance coverage in deprived postcodes.

Obesity prevalence in high-income countries tracks socioeconomic status, with meta-analyses confirming 1.5- to 2-fold higher rates among women in the lowest income strata. England's policy emphasis on individual behavior change has repeatedly failed to narrow these gaps, as documented in reviews of 14 national strategies from 1992-2020. Meanwhile, NICE criteria for tirzepatide target 3.4 million adults, yet phased NHS rollout will reach only 220,000 in primary care over three years, leaving private access as the de-facto early route.

Continued reliance on private payment will widen outcome disparities unless NHS capacity expands faster or means-tested subsidies are introduced. Next required evidence includes individual-level income data linked to prescription records and longitudinal tracking of cardiometabolic outcomes across deprivation strata.